Deep Longevity
corporateWebsite
field
Science
sub field
AI / MLBiotechLongevity
approach
Applied
Fund rating
0.0 / 35
0 published reviews
No per-dimension scores yet.
Published reviews
About
Relevant as an AI-for-longevity company: the evidence says Deep Longevity launched with Series A financing and works on AI-discovered biomarkers of aging to tackle aging-related diseases. That overlaps with OpenDrugs' AI-based evidence extraction and aging-focused substance intelligence.